Search research articles
Contact Us
Filters
Showing results (101-110 of 147) with videos related to
Page
of 15
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
February 2, 2006
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response
P J Hesketh, S M Grunberg, J Herrstedt, et al.
European Journal of Pain (London, England)
|
September 18, 2001
Improving the quality of pain treatment by a tailored pain education programme for cancer patients in chronic pain
R de Wit, F van Dam, S Loonstra, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 1996
Surveillance versus adjuvant chemotherapy in stage I non-seminomatous testicular cancer: a decision analysis
A M Stiggelbout, G M Kiebert, J C de Haes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1996
Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained
R de Wit, P I Schmitz, J Verweij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1997
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group
R de Wit, G Stoter, S B Kaye, et al.
Journal of Advanced Nursing
|
April 10, 1999
Daily pain assessment: value for nurses and patients
M de Rond, R de Wit, F van Dam, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 14, 2005
What is the role of dose-dense therapy?
M E L van der Burg, A van der Gaast, I Vergote, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 10, 2010
A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)
G Daugaard, I Skoneczna, N Aass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 1998
Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer
E W Steyerberg, A Gerl, S D Fossá, et al.
Cancer Chemotherapy and Pharmacology
|
August 14, 1999
Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours
V R Nannan Panday, R de Wit, J H Schornagel, et al.
Page
of 15
Search research articles
Search
Showing results (101-110 of 147) with videos related to
Sort By:
Page
of 15
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
February 2, 2006
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response
P J Hesketh, S M Grunberg, J Herrstedt, et al.
European Journal of Pain (London, England)
|
September 18, 2001
Improving the quality of pain treatment by a tailored pain education programme for cancer patients in chronic pain
R de Wit, F van Dam, S Loonstra, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 1996
Surveillance versus adjuvant chemotherapy in stage I non-seminomatous testicular cancer: a decision analysis
A M Stiggelbout, G M Kiebert, J C de Haes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1996
Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained
R de Wit, P I Schmitz, J Verweij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1997
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group
R de Wit, G Stoter, S B Kaye, et al.
Journal of Advanced Nursing
|
April 10, 1999
Daily pain assessment: value for nurses and patients
M de Rond, R de Wit, F van Dam, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 14, 2005
What is the role of dose-dense therapy?
M E L van der Burg, A van der Gaast, I Vergote, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 10, 2010
A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)
G Daugaard, I Skoneczna, N Aass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 1998
Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer
E W Steyerberg, A Gerl, S D Fossá, et al.
Cancer Chemotherapy and Pharmacology
|
August 14, 1999
Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours
V R Nannan Panday, R de Wit, J H Schornagel, et al.
Page
of 15